Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Consensus Price Target of $20.18 According to Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) have been assigned an average recommendation of “Moderate Buy” from the sixteen brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $20.67.

A number of equities research analysts recently weighed in on ORIC shares. Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. HC Wainwright lifted their target price on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Stifel Nicolaus started coverage on Oric Pharmaceuticals in a report on Friday, June 12th. They issued a “buy” rating and a $14.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Friday, July 17th. Finally, Benchmark reaffirmed a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th.

Insider Buying and Selling

In related news, CFO Dominic Piscitelli sold 13,400 shares of the company’s stock in a transaction on Monday, September 28th. The shares were sold at an average price of $13.53, for a total value of $181,302.00. Following the completion of the sale, the chief financial officer owned 69,828 shares in the company, valued at $944,772.84. This represents a 16.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 91,000 shares of company stock valued at $1,243,532. 5.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Oric Pharmaceuticals during the second quarter worth about $73,904,000. Siren L.L.C. lifted its position in Oric Pharmaceuticals by 197.6% during the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after acquiring an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Oric Pharmaceuticals by 19.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock valued at $18,637,000 after purchasing an additional 244,060 shares during the last quarter. Algert Global LLC grew its stake in shares of Oric Pharmaceuticals by 791.3% in the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock valued at $13,162,000 after purchasing an additional 1,078,943 shares during the last quarter. Finally, Braidwell LP increased its holdings in shares of Oric Pharmaceuticals by 7.7% in the second quarter. Braidwell LP now owns 1,214,540 shares of the company’s stock valued at $13,153,000 after purchasing an additional 86,500 shares during the period. 95.05% of the stock is currently owned by institutional investors and hedge funds.

Oric Pharmaceuticals Trading Up 2.4%

ORIC stock opened at $12.49 on Tuesday. The stock has a market cap of $1.29 billion, a P/E ratio of -9.25 and a beta of 0.99. Oric Pharmaceuticals has a twelve month low of $7.23 and a twelve month high of $14.93. The company’s 50 day moving average is $12.99 and its two-hundred day moving average is $10.87.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.02). On average, equities research analysts predict that Oric Pharmaceuticals will post -1.53 earnings per share for the current year.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research is centered on mechanisms that enable tumors to resist or evade treatment, with the goal of restoring sensitivity to established cancer therapies and improving patient outcomes.

Oric’s pipeline has included investigational small-molecule therapies designed to target cancer biology and treatment resistance. These programs include ORIC-533, an oral inhibitor of CD73 being studied in oncology, and ORIC-944, an oral allosteric inhibitor of EED, a component of the polycomb repressive complex 2.